Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | FABP6 | P51161 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 2/20 | 0.36 |
| ▸ | BACE1 | P56817 | 2/20 | 0.36 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.36 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14720750 | 0.85 | HRH3 (0.46) | HRH3POLBHDAC1FABP6 | |
| SCHEMBL14720930 | 0.81 | HRH3 (0.43) | HRH3POLBHDAC1FABP6ACHE | |
| SCHEMBL14721114 | 0.78 | SLC18A3 (0.53) | HRH3POLBHDAC1FABP6ACHE | |
| SCHEMBL14720596 | 0.75 | HDAC1 (0.53) | HRH3POLBHDAC1 | |
| SCHEMBL16055301 | 0.74 | ACHE (0.52) | HRH3POLBHDAC1FABP6ACHE | |
| SCHEMBL4206550 | 0.74 | ACHE (0.58) | HRH3POLBFABP6ACHEBACE1 | |
| SCHEMBL17455542 | 0.74 | HRH3 (0.50) | HRH3POLBHDAC1FABP6ACHE | |
| SCHEMBL14723242 | 0.74 | SRD5A2 (0.47) | HRH3 | |
| SCHEMBL14730640 | 0.73 | HRH3 (0.43) | HRH3POLBHDAC1FABP6ACHE | |
| SCHEMBL14730983 | 0.73 | HRH3 (0.43) | HRH3POLBHDAC1FABP6ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013027001-A1 | COMPOUNDS AND THEIR USE TO TREAT HISTAMINE H3 RELATED DISORDERS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-02-28 | — | — | WO | disclosed |